JAMES SAPIRSTEIN - 29 Dec 2023 Form 4 Insider Report for First Wave BioPharma, Inc. (FWBI)

Role
Chairman, President and CEO, Director
Signature
/s/ James Sapirstein
Issuer symbol
FWBI
Transactions as of
29 Dec 2023
Transactions value $
$0
Form type
4
Filing time
03 Jan 2024, 19:55:46 UTC
Previous filing
06 Oct 2023
Next filing
17 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FWBI Common Stock Award $0 +17.7K +1056.22% $0.00 19.3K 29 Dec 2023 Direct F1, F3
transaction FWBI Common Stock Award $0 +20K +103.46% $0.00 39.3K 02 Jan 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 29, 2023, the Reporting Person was granted 17,660 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest upon closing of the Issuer's proposed acquisition of ImmunogenX, Inc.
F2 On January 2, 2024, the Reporting Person was granted 20,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.
F3 Includes unvested RSUs.